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ABSTRACT  
Objective: To develop and validate a simple, sensitive and isocratic reverse phase high performance liquid chromatography (RP-HPLC) method for the 
simultaneous determination of olmesartan medoxomil (OLM), amlodipine besylate (AML) and cilnidipine (CIL) in pharmaceutical tablet formulation. 
Methods: In this work we have taken 2 combinations, combination 1-OLM & AML and combination 2-OLM & CIL. HPLC analysis was carried out by 
using reverse phase isocratic elution with a C 18 column and a mobile phase of 0.05 M ammonium acetate, acetonitrile and methanol in the ratio of 
30:50:20, v/v, pH was adjusted to 7.3. Detection of the analyte was achieved by using UV detector at 240 nm. 
Results: The retention time of olmesartan medoxomil, amlodipine besylate and cilnidipine were 2.2, 3 and 4.5 minutes respectively. Linearity of the 
method was found to be in the concentration range of 10-100µg/ml for olmesartan medoxomil, 5-50µg/ml for amlodipine and 10-100µg/ml for 
cilnidipine. The correlation coefficient value was greater than 0.999 for all the analytes. 
Conclusion: The method was validated as per ICH guidelines and is applied for the estimation of these components simultaneously in 
pharmaceutical tablet formulation.  
Keywords: HPLC, Acetonitrile, Olmesartan, Amlodipine, Cilnidipine.  
 
INTRODUCTION  
Olmesartan medoxomil (OLM) is a pro drug that hydrolysed to 
olmesartan during absorption [1-3]. Olmesartan is a competitive and 
selective Angiotensin II receptor antagonist. The hydrolysis of 
olmesartan medoxomil occurs readily by the action of esterase 
which is present abundantly in gastro intestinal tract, liver and 
plasma. It is used alone or with other antihypertensive agents to 
treat hypertension [4, 5]. It is chemically designated as 5-methyl-2-
oxo-1, (3-dioxolen-4-yl) methoxy-4-(1-hydroxy-1-methylethyl)-2-
proply-1-{4-[2-(tetrazol-5-yl)-phenyl] phenyl} methylimidazol-5-
carboxylate [6]. Olmesartan is also beneficial in animals and is a 
strong agent to show activity against atherosclerosis, liver disorders 
and diabetic nephropathy [7, 8]. Amlodipine besylate (AML) is 
chemically known as 3-ethyl-5-methyl (±)-2-[(2aminoethoxy) 
methyl]-4-(2-chlorophenyl)-1, 4-dihydro-6-methyl-3, 5-pyridine 
dicarboxylate, monobenzene sulphonate is long acting calcium 
channel blocker [9, 10] used to treat hypertension and angina. 
Amlodipine blocks the transmembrane influx of calcium ions into 
vascular smooth muscle and cardiac muscle [11-13]. It is 
metabolized in the liver and metabolites are mostly excreted in 
urine together with less than 10% of the dose as unchanged drug 
[14, 15]. Cilnidipine (CIL) is the novel calcium antagonist 
accompanied with L-type and N-type calcium channel blocking 
function [16]. It is chemically, 1, 4-Dihydro-2, 6-dimethyl-4-(3-
nitrophenyl)-3, 5-pyridine di carboxylic acid 2-methoxy ethyl (2E)-
3-phenyl-2-propenyl ester [17]. It reduces the incidence of pedal 
edema unlike amlodipine. It does not cause reflex tachycardia. It is 
superior to amlodipine in preventing the progression of proteinuria 
in patients with hypertension and chronic renal disease [18]. Most 
hypertensive patients require more than one agent in order to 
achieve adequate blood pressure control. Fixed dose combination 
antihypertensive treatments such as OLM/AML or OLM/CIL have 
advantage over monotherapy including increased efficacy, reduced 
side effect and lower cost. Several analytical methods have already 
been developed for the determination of olmesartan, amlodipine 
and cilnidipine either individually or in combination with other 
drugs [19-21]. According to the information extracted from 
literature, till date there is no method reported for the simultaneous 
determination of olmesartan medoxomil, amlodipine besylate and 
cilnidipine in pharmaceutical formulation. Aim of present work is to 
develop simple, precise and accurate RP HPLC method for 
simultaneous determination of olmesartan medoxomil, amlodipine 
besylate and cilnidipine in pharmaceutical formulation. The 
developed method can be applied successfully to quality control and 
other analytical purposes.  
MATERIALS AND METHODS  
Chemicals and reagents  
The working standard Olmesartan medoxomil was gifted by Madras 
pharmaceuticals, Chennai. Amlodipine besylate was gifted by Strides 
Arco lab Ltd, Bangalore and cilnidipine working standard was gifted 
by J. B. Chemicals & pharmaceuticals Ltd, Mumbai. Combination 
products Amlovas-OL and Nexovas-O manufactured by Macleods 
pharmaceuticals Pvt Ltd, Mumbai with label claim olmesartan 
medoxomil 20 mg, amlodipine besylate 5 mg and olmesartan 
medoxomil 20 mg, cilnidipine 10 mg was purchased from local 
market. Acetonitrile and Methanol (HPLC grade) purchased from 
Himedia Laboratories Pvt Ltd, Mumbai. Ammonium acetate (Extra 
pure) was purchased from Finar chemicals Ltd, Ahmadabad. The 
0.45 µm nylon filters were purchased from Millipore India pvt Ltd. 
Whatmann filter paper No. 41 purchased from the local market. 
Purified water for chromatography was obtained from Mille-Q 
system was used throughout an experiment.  
Apparatus and chromatographic conditions  
HPLC apparatus consisting of Waters 515 systems with binary 
pump, Rheodyne manual injector with a 20 µl loop and coupled with 
UV detector (Waters 2489). Data was integrated by Waters 
Empower 2 software and used for development and evaluation of 
this method. A chromatographic separation was achieved on Waters 
Symmetry C 18 column-3.5 µm (4.6 ×75 mm). Mobile phase consist 
of 0.05M ammonium acetate, acetonitrile and methanol in ratio of 
(30:50:20) v/v. The mobile phase pumped through the column with 
flow rate of 0.3 ml/min in isocratic mode. The mobile phase filtered 
through 0.45 µm nylon filter and degassed in ultrasonicator bath for 
30 minutes prior to use. Injection volume was 20 µl throughout the 
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study. Based on the response of all the analyte the optimum 
wavelength 240 nm was selected. HPLC system was operated at room 
temperature (25±2 °C)  
Preparation of standard solution  
1 mg/ml of standard stock solutions of drug substance were 
prepared in methanol. Prior to measurement, stock solutions of 
olmesartan medoxomil, amlodipine besylate and cilnidipine were 
diluted with mobile phase so as to prepare working standard 
solution of 100µg/ml. various dilutions were made to prepare 
working solutions. HPLC analysis was carried out with 20 µl aliquots 
of various concentration of working solutions.  
Assay procedure for pharmaceutical preparation  
Ten tablets of each formulation Amlovas OL (composition 1) and 
Nexovas O (composition 2) were accurately weighed and finely 
powdered. A quantity of the powdered tablets equivalent to 20 mg 
OLM and 5 mg AML for combination 1 and 20 mg OLM and 10 mg 
CIL for combination 2 was accurately weighed and transferred to 50 
ml volumetric flask separately. 50 ml of methanol was added each 
volumetric flask and extraction were performed mechanically for 20 
minutes and sonicated for 30 minutes. The dilution was made with 
methanol to give the solution containing 40 µg/ml of OLM and 10 
µg/ml of AML for combination 1, 40 µg/ml of OLM and 20 µg/ml of 
CIL for combination 2. From each of these solutions, 1 ml of extract 
was transferred to 10 ml volumetric flasks and diluted to the mark 
with the mobile phase. The working tablet solution containing 4 
µg/ml OLM, 1 µg/ml AML for combination 1 and 4 µg/ml OLM, 2 
µg/ml CIL of combination 2.20 µl of sample from each working 
tablet solution was directly injected in to HPLC column. All 
measurements were repeated six times for each concentration. 
Nominal contents of pharmaceutical preparation were calculated 
using regression equation of calibration graph.  
Method validation  
The optimized RP-HPLC method was validated according to the ICH 
guidelines [22] with respect to specificity, accuracy, precision, 
linearity, limit of detection, limit of quantification and robustness.  
Specificity  
The specificity of the method was performed by analysis of drug 
standard and samples. The mobile phase resolved both drugs very 
efficiently. The peak purity of OLM, AML and CIL was determined by 
comparing the retention time  
Precision  
Precision of an analytical method was verified by repeatability and 
intermediate precision studies. Repeatability studies were performed 
by analysis of three different concentrations (30.2, 60.4 and 90.7 
µg/ml for OLM and CIL, 15.2, 30.1 and 45.2 µg/ml for AML) of the 
drugs for six times on the same day. The intermediate precision of the 
method was checked by repeating studies on three different days.  
Accuracy  
Accuracy of the method was evaluated by recovery studies. It was 
employed by the standard addition method. Three levels of solution 
were made at nominal analytical concentration such as 40%, 50%, 
and 60% respectively. Each level was made in triplicate.  
Linearity  
Linearity of the method was studied by injecting six concentration of the 
drug prepared in mobile phase in the range of 10-100µg/ml of OLM and 
CIL(10,20,40,60,80,100µg/ml), 5-50µg/ml for AML (5,10,20,30,40,50 
µg/ml) respectively in triplicate into the HPLC system keeping the 
injection volume constant. The peak areas were plotted against the 
corresponding concentration to obtain calibration graphs.  
Limit of detection (LOD) and limit of quantitation (LOQ)  
The limit of detection LOD and quantification LOQ was determined 
based on the standard deviation of response and slope. Detection 
limit and quantification limit were calculated by [(3.3 ×σ)/S and 
(10×σ)/S] respectively. Where ‘σ’ is the standard deviation of the 
response and ‘S’ is slope of the calibration curve.  
Robustness  
The robustness is the capacity of the method to remain unaffected 
by small but deliberate change in chromatographic conditions. 
Robustness of the developed method was tested by studying the 
influence of small change in flow rate (±0.1 ml/min) and change in 
pH of the buffer (±0.2units).  
RESULTS AND DISCUSSION  
Method optimization  
In this work, a simple, sensitive and validated HPLC method has 
been developed for simultaneous estimation of olmesartan OLM, 
amlodipine AML and cilnidipine CIL using liquid chromatography 
with ultraviolet visible detection. A number of mobile phase were 
initially attempted to elute three components simultaneously.  
The main focus was to achieve sharp and Gaussian shaped peak with 
tailing less than 1.5 and resolution greater than 1.5. In order to 
achieve this goal acetonitrile, methanol, water in different 
proportion were used but no sharp peaks were observed. 
Ammonium acetate was then added to increase the polarity of 
mobile phase. A 0.05M concentrations of ammonium acetate at pH 
7.3 with acetonitrile and methanol in the ratio of 30:50:20 v/v was 
strong enough to elute the three components with resolution greater 
than 5, theoretical plate greater than 3500 and tailing less than 1.5 
for the three components. The best mobile phase composition was 
then found to be 0.05M ammonium acetate pH 7.3, acetonitrile and 
methanol in the ratio of 30:50:20 (v/v) Under mentioned 
chromatographic condition sharp peaks belonging to olmesartan 
medoxomil, amlodipine besylate and cilnidipine were obtained at 
retention time of 2.2, 3 and 4.5 minutes respectively (fig. 1 and 2). 
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Fig. 2: Chromatogram for sample on simultaneous estimation of OLM, AML and CIL 
 
Method validation  
Linearity  
Linearity was studied by preparing the standard solution at different 
concentration levels. The linearity range for OLM, AML, and CIL was 
found to be 10-100 µg/ml, 5-50 µg/ml and 10-100µg/ml respectively. 
The regression equation for OLM, AML and CIL were found to be 
Y=5.24e+004X-7.13e+004, Y=6.98e+004X-2.91e+004 and Y=1.12e+ 
005X-2.47e+005 with correlation coefficient (R2) 0.998, 0.999 and 
0.998 respectively for all the compounds, the coefficients of 
determination prove that the method was linear in specific range.  
Precision  
The result of the repeatability and intermediate precision 
experiment are shown in table 1. The developed method was found 
to be precise as the RSD values for repeatability and intermediate 
precision studies were<2 %, respectively as recommended by ICH 
guidelines (ICH Q2 (R1), 2005). 
Accuracy  
The accuracy of the method was performed by the standard addition 
technique. Three levels of solution were made which corresponds to 
40, 50, and 60 % of the nominal analytical concentration. Each level 
was made in triplicate. The recovery and relative standard deviation 
for each of the analytes are given table 2. From the recovery studies 
it is evidence that the method is highly accurate and can give 
excellent results. 
Limit of quantitation and limit of detection  
Limit of quantification (LOQ) and Limit of detection (LOD) can be 
determined based on visual evaluation, signal-to noise approach and 
standard deviation of the response and slope. The LOD of OLM was 
0.26 µg/ml, AML is 0.05µg/ml and CIL is 0.22µg/ml was determined. 
The LOQ of OLM is 0.79µg/ml, AML is 0.14µg/ml and CIL is 0.67µ/ml 
was determined. 
Specificity  
The peak purity of OLM, AML and CIL was assessed by comparing 
the retention time of standard OLM, AML and CIL. Good correlation 
was obtained between the retention time of the standard and 
sample of OLM, AML and CIL. Thus, the method was specific for OLM, 
AML and CIL. 
Robustness  
Robustness of the method was performed by small deliberate 
changes in the optimized chromatographic condition such as flow 
rate (±0.1 ml/min) and PH of ammonium acetate buffer (±0.2units). 
The result shown that have the negligible effect on retention time, 
recoveries and peak area of three drugs indicating the developed 
method is robust. 
  
Table 1: Precision of the proposed HPLC method 
Drug Concentration (µg/ml) N  Within day precision Between dayprecision  
 Mean  RSD % Mean  RSD% 
Olm 30.2 6 30.59 1.16 29.98 1.34 
 60.4 6 60.54 0.59 61.43 0.52 
 90.7 6 90.70 0.52 90.56 0.51 
Aml 15.2 6 15.68 1.16 15.86 1.34 
 30.1 6 30.51 1.12 30.53 1.15 
 45.2 6 45.58 0.82 44.85 0.60 
CIL 30.2 6 30.32 1.29 29.86 0.89 
 60.4 6 60.68 0.67 61.04 0.83 
 90.7 6 90.63 0.52 90.27 0.51 
 
Table 2: Accuracy of the proposed HPLC method 
Drug Level % Concentration (µg/ml) Amount recovered (µg/ml) % Recovery %RSD 
OLM 40 40 40.15 100.38  1.16 
 50 50 49.66  99.32  0.97 
 60 60 59.78  99.64  1.06 
 AML 40 20 19.96  99.83  1.55 
 50 25 24.64  98.58  0.79 
 60 30 30.36  101.27  1.66 
 CIL 40 40 40.24  100.6 0.92 
 50 50 49.77  99.54 0.99 
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Table 3: Assay of commercial tablets 
 Drug Label claim (mg) Drug content(%)±SD  % R. S. D 
Combination-I 
OLM  20  99.33±0.97   0.98 
 AML  5  98.59±0.78  0.79 
Combination-II 
 OLM  20  99.33±0.97  0.98 
 CIL  10  99.54±0.99  0.99 
 
Analysis of commercial formulation  
The amount of OLM, AML and CIL per tablet was calculated by 
extrapolating the value of an area from the calibration curve. 
Analysis procedure was repeated six times with the tablet 
formulation. The result of analysis of the tablet formulation is 
reported in table 3. 
DISCUSSION 
In previous method Olmesartan Medoxomile, Amlodipine Besylate and 
Hydrochlorothiazide combination, cilnidipine and olmesartan 
medoxomil combination was estimated by RP-HPLC in tablet dosage 
form. Here two combinations such as OLM and AML, OLM andCIL 
combinations were estimated simultaneously by HPLC. So this is new 
method in such combination. The retention time was less than 5 
minutes. The method was validated as per ICH guidelines (ICH Q2 (R1), 
2005). The method was simple, selective, cost effective and reproducible 
and can be reliably used by almost every drug laboratory. 
CONCLUSION  
HPLC method was developed and validated as per ICH guidelines (ICH 
Q2 (R1), 2005). It is simple, selective, cost effective and reproducible 
and can be reliably used by almost every drug laboratory. The method 
enables simultaneous determination of OLM, AML and CIL in 
pharmaceutical preparation. Due to the fact that these substances are 
mainly used as combination for hypertension therapy, this new 
procedure is very important. In the process of developing the method 
and validation studies were carried out. Finally the method was 
applied to analysis for two drug formulation including combination I 
and II, the run time was less than 5 minutes.  
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